(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments...
Stats | |
---|---|
今日成交量 | 4.69M |
平均成交量 | 4.77M |
市值 | 26.92B |
EPS | €0 ( 2024-03-04 ) |
下一个收益日期 | ( €2.32 ) 2024-05-14 |
Last Dividend | €2.40 ( 2023-05-02 ) |
Next Dividend | €0 ( N/A ) |
P/E | -9.16 |
ATR14 | €0.0150 (0.05%) |
音量 相关性
Bayer AG 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Bayer AG 相关性 - 货币/商品
Bayer AG 财务报表
Annual | 2023 |
营收: | €47.64B |
毛利润: | €27.89B (58.54 %) |
EPS: | €-2.99 |
FY | 2023 |
营收: | €47.64B |
毛利润: | €27.89B (58.54 %) |
EPS: | €-2.99 |
FY | 2022 |
营收: | €50.74B |
毛利润: | €30.87B (60.84 %) |
EPS: | €4.22 |
FY | 2021 |
营收: | €44.08B |
毛利润: | €27.27B (61.85 %) |
EPS: | €1.018 |
Financial Reports:
No articles found.
Bayer AG Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€2.40 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €1.279 | 2000-05-02 |
Last Dividend | €2.40 | 2023-05-02 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 25 | -- |
Total Paid Out | €43.29 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.56 | -- |
Div. Sustainability Score | 3.23 | |
Div.Growth Potential Score | 2.19 | |
Div. Directional Score | 2.71 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PER.DE | Ex Dividend Knight | 2023-07-05 | Annually | 0 | 0.00% | |
BAYN.DE | Ex Dividend Junior | 2023-05-02 | Annually | 0 | 0.00% | |
HNR1.DE | Ex Dividend Junior | 2023-05-04 | Annually | 0 | 0.00% | |
SCT.DE | Ex Dividend Knight | 2023-07-27 | Annually | 0 | 0.00% | |
COK.DE | Ex Dividend Junior | 2023-06-15 | Annually | 0 | 0.00% | |
KRN.DE | Ex Dividend Knight | 2023-05-24 | Annually | 0 | 0.00% | |
185.DE | Ex Dividend Junior | 2023-08-07 | Quarterly | 0 | 0.00% | |
TRVC.DE | Ex Dividend Junior | 2023-08-04 | Quarterly | 0 | 0.00% | |
DYH.DE | Ex Dividend Knight | 2023-11-14 | Quarterly | 0 | 0.00% | |
MUX.DE | Ex Dividend Junior | 2023-07-11 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0617 | 1.500 | -1.235 | -1.852 | [0 - 0.5] |
returnOnAssetsTTM | -0.0238 | 1.200 | -0.795 | -0.954 | [0 - 0.3] |
returnOnEquityTTM | -0.0816 | 1.500 | -2.02 | -3.03 | [0.1 - 1] |
payoutRatioTTM | -0.809 | -1.000 | -8.09 | 8.09 | [0 - 1] |
currentRatioTTM | 1.259 | 0.800 | 8.70 | 6.96 | [1 - 3] |
quickRatioTTM | 0.784 | 0.800 | -0.0946 | -0.0757 | [0.8 - 2.5] |
cashRatioTTM | 0.201 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.355 | -1.500 | 4.08 | -6.11 | [0 - 0.6] |
interestCoverageTTM | 0.595 | 1.000 | -0.891 | -0.891 | [3 - 30] |
operatingCashFlowPerShareTTM | 4.85 | 2.00 | 8.38 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.05 | 2.00 | 8.97 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.332 | -1.500 | 4.67 | -7.01 | [0 - 2.5] |
grossProfitMarginTTM | 0.585 | 1.000 | 3.58 | 3.58 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0333 | 1.000 | -1.333 | -1.333 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.109 | 1.000 | -0.507 | -0.507 | [0.2 - 2] |
assetTurnoverTTM | 0.386 | 0.800 | -0.759 | -0.607 | [0.5 - 2] |
Total Score | 3.23 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -9.15 | 1.000 | -1.026 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0816 | 2.50 | -1.297 | -3.03 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.05 | 2.00 | 9.32 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 8.76 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 4.85 | 2.00 | 8.38 | 10.00 | [0 - 30] |
payoutRatioTTM | -0.809 | 1.500 | -8.09 | 8.09 | [0 - 1] |
pegRatioTTM | 0.117 | 1.500 | -2.55 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.100 | 1.000 | 10.00 | 0 | [0.1 - 0.5] |
Total Score | 2.19 |
Bayer AG
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。